China Sky One Medical, Inc. to Conduct Non-Deal Roadshow in Hong Kong and Singapore

HARBIN, China, July 28 /PRNewswire-Asia-FirstCall/ — China Sky One
Medical, Inc. (“China Sky One Medical” or “the Company”) (Nasdaq: CSKI), a
leading fully integrated pharmaceutical company producing over-the-counter
drugs in the People’s Republic of China (“PRC”), today announced that the
Company is scheduled to launch a non-deal roadshow (“NDR”) in Hong Kong and
Singapore in early August, 2009.

China Sky One Medical’s Chief Executive Officer, Mr. Yan-qing Liu, and
Chief Financial Officer, Mr. Stanley Hao will participate in the NDR to meet
with institutional investors and equity analysts from August 4 to August 5 in
Hong Kong and on August 6 in Singapore.

“This NDR represents our commitment to maintain communication with
investors and better understand their expectations,” said Mr. Yan-qing Liu,
Chairman and CEO of China Sky One Medical. “We will continue this effort by
pursuing best practices investor relations activities as we work to build
lasting value to our shareholders.”

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company.
The Company engages in the manufacturing, marketing and distribution of
pharmaceutical, medicinal and diagnostic products. Through its wholly-owned
subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company
(“TDR”), Harbin First Bio-Engineering Company Limited (“First”), Heilongjiang
Tianlong Pharmaceutical, Inc. (“Tianlong”) and Peng Lai Jin Chuang
Pharmaceutical Company (“Jin Chuang”) the Company manufactures and distributes
over-the-counter pharmaceutical products, which make up its major revenue
source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by the use
of forward- looking terminology such as “believe,” “expect,” “may,” “will,”
“should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative
thereof or comparable terminology. Such statements typically involve risks and
uncertainties and may include financial projections or information regarding
the non-deal roadshow. Actual results could differ materially from the
expectations reflected in such forward-looking statements as a result of a
variety of factors, including the risks associated with the effect of changing
economic conditions in The People’s Republic of China, variations in cash flow,
reliance on collaborative retail partners and on new product development,
variations in new product development, risks associated with rapid
technological change, and the potential of introduced or undetected flaws and
defects in products, and other risk factors detailed in reports filed with the
Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Stanley Hao, CFO
     Tel:   +86-451-5399-4069
     Email: china_sky_one@yahoo.cn

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com

SOURCE China Sky One Medical, Inc.